Screening programmes, better diagnostic sensitivity, and biomarker-guided precision oncology have improved the outlook for several types of cancer, such as breast, colorectal and prostate. However, these advances have not been achieved in all cancers. Advanced hepatocellular carcinoma (HCC) and drug resistant cancers continue to be therapeutic challenges that reduce patient survival. Against this backdrop, several laboratories in the NCCS are focused on developing new therapeutics to address these grim clinical situations.
Subscribe to our mailing list to get the updates to your email inbox...
11 Hospital Drive, Singapore 169610 +65 6436 8000